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Quantitative detection of codeine in human plasma 
using surface-enhanced Raman scattering via 
adaptation of the isotopic labelling principle† 
 
Abdu Subaihi,a Howbeer Muhamadali,a Shaun T. Mutter,a,c Ewan 
Blanch,b David I. Ellisa and Royston Goodacre*a 
 
In this study surface enhanced Raman scattering (SERS) combined with the isotopic labelling (IL) principle 
has been used for the quantification of codeine spiked into both water and human plasma. Multivariate 
statistical approaches were employed for the analysis of these SERS spectral data, particularly partial least 
squares regression (PLSR) which was used to generate models using the full SERS spectral data for 
quantification of codeine with, and without, an internal isotopic labelled standard. The PLSR models pro-
vided accurate codeine quantification in water and human plasma with high prediction accuracy (Q2). In 
addition, the employment of codeine-d6 as the internal standard further improved the accuracy of the 
model, by increasing the Q2 from 0.89 to 0.94 and decreasing the low root-mean-square error of predic-
tions (RMSEP) from 11.36 to 8.44. Using the peak area at 1281 cm−1 assigned to C–N stretching, C–H 
wagging and ring breathing, the limit of detection was calculated in both water and human plasma to be 0.7 
µM (209.55 ng mL−1) and 1.39 µM (416.12 ng mL−1), respectively. Due to a lack of definitive codeine 
vibrational assignments, density functional theory (DFT) calculations have also been used to assign the 
spectral bands with their corresponding vibrational modes, which were in excellent agreement with our 
experimental Raman and SERS findings. Thus, we have successfully demonstrated the application of 
SERS with isotope labelling for the absolute quantification of codeine in human plasma for the first time 
with a high degree of accuracy and reproducibility. The use of the IL principle which employs an isotopolog 
(that is to say, a molecule which is only diﬀerent by the substitution of atoms by isotopes) improves 
quantifi-cation and reproducibility because the competition of the codeine and codeine-d6 for the metal 
surface used for SERS is equal and this will oﬀset any diﬀerence in the number of particles under analysis 
or any 
 
fluctuations in laser fluence. It is our belief that this may open up new exciting opportunities for testing 
SERS in real-world samples and applications which would be an area of potential future studies. 
 
 
Introduction 
 
Codeine (3-methylmorphine) is an organic compound belong-ing to 
a group of medicines commonly known as opioids. In many 
countries codeine is regulated under narcotic laws. Within the UK 
for example, codeine in its various forms is regulated by the Misuse 
of Drugs Act (1971) as a class B con-trolled substance, with only 
lower-strength combinations con-taining a maximum of 12.8 mg of 
codeine per dosage available 
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over the counter without a prescription.1 Codeine is a potent 
analgesic drug which is commonly used as a therapeutic agent for 
the treatment of low, moderate and chronic pain. However, long-
term use of codeine may also lead to addiction and over-doses can 
even cause severe liver damage, disorders and res-piratory 
depression.2,3 
 
Various analytical approaches have been reported for the 
detection of codeine in biological fluids such as gas chromato-
graphy tandem mass spectrometry (GC-MS),4–6 high perform-ance 
liquid chromatography (HPLC) coupled to either ultra-violet 
detection7,8 or tandem mass spectrometric detection (HPLC-MS),9 
thin-layer chromatography (TLC)10 and capillary electrophoresis 
(CE).11 However, these well-established methods have some 
drawbacks, such as the requirement for lengthy sample processing 
steps (e.g. liquid–liquid extrac-tion or solid–phase extraction) to 
improve sensitivity and selectivity, requiring skilled laboratory 
personnel and complex 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
instrumentation. Therefore, it would be advantageous for many 
applications to develop simple, rapid, accurate, sensitive, relatively 
inexpensive, portable and on-site detection approaches that are 
capable of monitoring drugs in various biological fluids.12 
 
Raman spectroscopy is a physicochemical vibrational 
spectroscopic technique that is based on the inelastic scatter-ing of 
light when it interacts with molecules, providing highly specific 
molecular fingerprints of the sample under 
 
analysis, which can be used for the accurate characterisation of 
analytes.13,14 However, due to the inherently weak Raman 
signal, typically only 1 in 106–108 photons are inelastically 
scattered; therefore, surface-enhanced Raman scattering (SERS) has 
been explored to overcome this issue by signifi-cantly improving the 
Raman signal through adsorption of an analyte of interest onto a 
roughened metal surface, which enhance the Raman eﬀ ect by 
several orders of magnitude 
 
yielding an ultra-sensitive and chemically selective analytical tool.15,16 
 
SERS has recently been applied to the analysis of various 
complex biological samples including: bacterial cells,17,18 whole-
blood and its components ( plasma, sera and red blood cells)19 and 
for the study of various diseases using blood serum and plasma.20–24 
Several studies have reported the application of SERS for the 
successful detection, identification and quantification of illicit 
drugs.25,26 Alharbi and colleagues also used this approach for the 
quantitative detection of the opioid tramadol in artificial urine.27 
Dong et al. employed (dynamic) D-SERS and support vector 
machines for the quanti-tative detection of methamphetamine in 
human urine.28 Andreou et al. also reported the detection of 
methamphet-amine in saliva samples using a microfluidic device 
which controlled the interaction between the drug, Ag nanoparticles, 
and the aggregation agent.29 Finally, in a more recent study, we have 
also demonstrated SERS as a powerful technique for the quantitative 
detection of the beta-blocker propranolol in human biofluids (serum, 
plasma, urine) when combined with chemometric approaches.30 
 
However, the application of SERS for the detection and 
quantification of drugs in complex biological media can face several 
challenges, most notably the reproducibility, accuracy and 
repeatability of the SERS signal which could be due to ran-domly 
distributed hot spots which occur during sample ana-lysis.31,32 
Therefore, in this study the IL principle combined with a portable 
Raman spectrometer has been employed to improve the quantitative 
detection of codeine in human plasma. This approach is based on the 
addition of a known constant quantity of isotopically labelled 
codeine (codeine-d6) as an internal standard. We show that this 
could be employed in a portable assay for the detection of such 
drugs at very low concentration in human biofluids. Our results 
clearly demon-strate the potential application of this strategy, 
combining IL with SERS, for development of quantitative detection 
of codeine in human plasma, providing a highly specific and 
accurate prediction of codeine concentrations with minimal error. 
 
Materials and methods 
 
Materials 
 
Silver nitrate (99.9%), trisodium citrate, sodium chloride, codeine, 
codeine-d6 and human plasma were all purchased from Sigma 
Aldrich (Dorset, United Kingdom). All plasma samples were sourced 
from the same analytical batch to reduce any batch-to-batch 
variation. Amicon Ultra 0.5 mL cen-trifugal filters (3 kDa) were 
purchased from Merck Millipore Ltd (Germany). All chemicals used 
were of analytical grade. 
 
Synthesis of silver nanoparticles 
 
The Lee and Meisel citrate reduction method33 was used to prepare 
the silver nanoparticles (AgNPs). Briefly, 90 mg of AgNO3 was 
dissolved in 500 mL of deionised water; the solu-tion was heated to 
boiling point, 1% aqueous solution of tri-sodium citrate (10 mL) was 
added to a stirring silver nitrate solution drop by drop. The mixed 
solution was left at boiling point for a further 15 min until a green-
milky silver colloid was observed, which proved to be stable and 
useable for several weeks following preparation. The colloid was 
assessed using UV-visible spectroscopy and scanning electron 
microscopy (SEM) and was very similar to that used in previously 
pub-lished studies.25,26,34,35 
 
Instrumentation 
 
Initial experiments were carried out to generate conventional Raman 
spectra of powdered codeine and codeine-d6, which were placed on a 
calcium fluoride (CaF2) disc and Raman spectra were recorded using 
633 nm excitation (see ESI† for more details of the conventional 
Raman measurements). 
 
SERS spectra were recorded using a DeltaNu Advantage portable 
Raman spectrometer (DeltaNu, Laramie, WY, USA), equipped with 
a 633 nm HeNe laser emitting ∼3 mW on to the sample. Daily 
calibration of the instrument was performed using a polystyrene 
internal standard as supplied by the instru-ment manufacturer. All 
samples were analysed within the 400 to 3400 cm−1 spectral range, 
with a spectral resolution of 8 cm−1 and the laser exposure time was 
set to 20 s for all samples. 
 
 
Sample preparation for SERS measurements 
 
Stock solutions (10 mL each) of human plasma and distilled water 
were spiked individually each with 1.5 mg of codeine and codeine-
d6. A serial dilution of unlabelled codeine with plasma (no water 
added) and water was then prepared at a range of concentrations for 
quantitative analysis, while the concentration of the stable isotope 
standard (codeine-d6) was kept fixed. Mixtures of either water or 
plasma spiked with unlabelled and labelled codeine were prepared at 
diﬀ erent codeine concentrations ranging from 0 µM to 140 µM. 
Amicon ultra-centrifugal filters were used to remove protein residues 
from plasma samples, 0.5 mL aliquots were transferred onto the filter 
tube and centrifuged at 14 000g for 30 min following the 
manufacturer’s recommended protocol. All plasma samples were 
then stored at −80 °C until required for analysis. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
To minimise any SERS signal variability as a result of diﬀ ering 
volumes of components, the colloid/analyte volume were kept at 200 
µL each and NaCl as an aggregation agent at 50 µL, resulting in a 
total 450 µL of solution for each sample. The resulting mixture was 
vortexed for 2 s and placed into the sample cell attachment, which 
was immediately interrogated by laser irradiation for 20 s. A total of 
five biological replicates and two analytical replicates were prepared 
for each biological matrix and for each concentration. 
 
 
Chemometrics SERS data processing 
 
MATLAB software R2013a (The Math Works Inc, Natwick, USA) 
was used to process all SERS spectral data. All SERS data were 
baseline corrected using asymmetric least squares (AsLS)36 and 
subjected to the supervised method of partial least squares regression 
(PLSR).37,38 PLSR is a multivariate quantitative regression 
technique generally used for predictive linear mod-elling, as 
reported previously by our research group.39,40 PLSR was also 
employed to generate separate models for predicting the 
concentration of codeine spiked into either water or plasma. The 
PLSR models were constructed using the entire SERS spectral data. 
Four separate PLSR models were generated from: (i) codeine spiked 
in water, (ii) a mixture of codeine/ codeine-d6 spiked in water, (iii) 
codeine spiked in plasma, (iv) a mixture of codeine/codeine-d6 
spiked in plasma. For each PLSR model, 50% of the data were used 
as the training set to calibrate the multivariate model. Once the 
models were cali-brated, the remaining data (test set) were used for 
the predic-tion of codeine concentrations and also were used for 
vali-dation purposes. 
 
 
 
Results and discussion 
 
Preliminary investigations were conducted using Raman spec-
troscopy with 633 nm excitation to analyse powdered samples (2–3 
µg) of codeine and codeine-d6. The chemical structures of these 
compounds are presented in Fig. 1, and the resulting Raman spectra 
are provided in (Fig. S1†) which illustrates the spectral shifts as a 
result of changes in the reduced mass of vibrations that involved 
deuterium (D, 2H) instead of hydro-gen. Due to limited information 
on Raman spectral band assignments of codeine and codeine-d6, 
quantum chemical 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 The chemical structures of codeine and codeine-d6 showing where 
CH3 were replaced with CD3. 
 
calculations based on density functional theory (DFT) have been 
used to confirm these peak shifts and their corres-ponding 
vibrational band assignments; we refer the reader to the ESI† for 
more details on the DFT calculations. The calcu-lated spectra were 
generated based on a gas phase environ-ment (Fig. S2†), but even 
with this assumption the details of the modelled spectrum are clearly 
in agreement with our experimental findings. Table S1† provides 
tentative assign-ments of the main bands aﬀ ected by the labelling 
process, which can be assigned to the CH stretching (2800 to 3200 
cm−1) region of unlabelled codeine, that are shifted to the CD 
stretching (2070 to 2260 cm−1) region for the codeine sample 
labelled with deuterium. As the concentrations of codeine that we 
wish to detect from human plasma are too low to be observed using 
conventional Raman, due to the inherent weakness of the Raman 
eﬀ ect mentioned above, SERS was therefore employed to improve 
the sensitivity and lower the detection limit of codeine in the 
biofluids under investigation. 
 
Initial optimizations of the SERS parameters for codeine 
detection were carried out by examining various factors, such as: the 
forms of metal nanoparticles, the aggregation agent, as well as the 
aggregation time used. Subsequently, the optimal conditions for 
SERS enhancement were achieved using a citrate-reduced silver 
colloid with sodium chloride as the aggregation agent which is 
similar to our previously published protocol.30 A previous study 
reported the SERS optimum con-ditions of codeine dissolved in 
water,41 where silver nano-particles with NaCl gave the highest 
enhancement at 633 nm and which further supported the 
optimization conditions used in our present study. 
 
Prior to analysing codeine in complex human plasma which 
contains many proteins and small molecules that may interfere with 
SERS, codeine was initially investigated in water, to reduce the 
complexity of the resulting spectra and also to facilitate accurate 
identification of the SERS peak shifts in samples containing labelled 
codeine. SERS spectra of codeine and codeine-d6 spiked into water 
are presented in Fig. 2a. The main bands aﬀ ected by the presence of 
the heavy isotope were found to be at 2953, 3028 and 3059 cm−1, 
corresponding to the symmetric C–H stretching of N–CH3, 
symmetric C–H stretching of O–CH3 and asymmetric C–H 
stretching of O– CH3, respectively. These were shifted to 2075, 2128 
and 2275 cm−1, with these vibrations being assigned to N–CD3, O– 
CD3 and O–CD3 in codeine-d6. A list of the main bands detected, 
and their corresponding assignments, are summar-ized in Table S1.† 
As shown previously, SERS of analytes directly in plasma was not 
possible.30 This is largely due to the high abundance of proteins in 
plasma (e.g., albumin) which may interfere with the aggregation of 
the SERS nanoparticles. Therefore, ultra-centrifugal filters were used 
to minimise protein content in these samples, a strategy we have very 
recently used successfully and further details of this can be found in 
the literature.30 The SERS spectra of codeine and codeine-d6 in 
plasma (see Fig. 2b) displayed similar peak shifts described above 
resulting from the presence of the heavy isotope. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Baseline-corrected SERS spectra of 100 µM codeine spiked into (a) water (b) human plasma. The blue spectra refer to codeine, red spectra belong 
to codeine-d6, and the green spectrum is collected from pure plasma. Annotations with arrow are bands that are assigned to specific vibrational modes 
(see Tables S1 and S2†). 
 
 
There were many features observed in the SERS spectra of pure 
plasma, the most significant peaks that could be assigned to plasma 
were at 644 and 1131 cm−1, which are attributed to tyrosine and D-
mannose, respectively;20,30 Table S2† summar-izes the main band 
assignments for pure plasma. In order to examine the limit of 
detection (LOD) of codeine in both water and plasma, the peak area 
at 1281 cm−1 (assigned to C–N stretch-ing, C–H wagging and ring 
breathing) was used to calculate the LOD, by plotting the area under 
this peak with varying concen-trations of codeine (Fig. S3a and b†). 
In these figures there is a slight sigmoidal shape to the curve for 
codeine, which is more accentuated in plasma compared to water. 
This is likely to be 
 
 
due to increased competition of the codeine for the surface of the 
colloid which, when it is present in the plasma, is competing with 
other components (viz. organic acids, salts, metabolites etc.) found 
naturally within human blood plasma. Based on 3 times the standard 
deviation of the response and the slope,42 the LOD in water and 
plasma were found to be 0.7 µM (209.55 ng mL−1) and 1.39 µM 
(416.12 ng mL−1), respectively. The higher LOD for codeine in 
plasma is for reasons just mentioned perhaps not surprising and is 
likely to be due to the presence of various mole-cular species in the 
plasma competing for binding with the metal surface, and restricting 
the interaction of the codeine molecules with the metal 
nanoparticles.43,44 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Representative PLS based predictions of concentration versus known concentrations of (a) codeine and (c) mixtures of codeine + codeine-d6 
spiked in water. Note that the concentration of codeine-d6 remained constant. The corresponding PLS loading plots are from (b) codeine alone, and 
(d) after employing the isotopic labelling with codeine-d6. 
 
 
Quantification of codeine in water and plasma samples were 
carried out by generating PLSR models using the whole SERS 
spectral data as described in the chemometrics section. The 
quantitative models were generated and calibrated using the SERS 
data of codeine alone and mixtures of codeine/ codeine-d6 spiked 
into water (Fig. 3a and c). A similar approach was also employed for 
the analysis of codeine and mixtures of codeine/codeine-d6 spiked 
into human plasma (Fig. 4a and c). The generated models 
demonstrated a slight improvement of prediction accuracy (Q2) from 
0.74 to 0.79 and from 0.89 to 0.94 in water and human plasma, 
respectively, when using the isotopic labelling approach. In addition, 
using this approach the root-mean-square error of prediction 
(RMSEP) also improved (i.e. decreased): from 11.41 to 7.75 and 
18.74 to 12.71 in water and human plasma, respectively. It is noted 
that the deviations of some samples are much larger than others in 
Fig. 4a and c and they are more likely due to the experimental 
factors. Table 1 contains a summary of the statistics for the PLSR 
models and also details the same stati- 
 
stics for the training set (viz. R2 and RMSECV). Additionally, the 
PLS component loadings are plotted to confirm the above findings 
by revealing the contributed bands of labelled codeine as peaks, at 
2075, 2128 and 2275 cm−1, as these were the main significant 
variables influenced by codeine-d6 in either water (Fig. 3b and d) or 
plasma (Fig. 4b and d). 
 
 
Conclusion 
 
Here, we have developed a simple and robust SERS-based method 
for the quantitative detection of the opioid codeine in water and 
human plasma. In addition, the application of the IL principle also 
improved the accuracy and precision of this approach. We have 
shown that the use of the IL principle by the addition of an 
isotopolog (i.e., a molecule which is only diﬀ erent by the 
substitution of atoms by isotopes) improves quantification and 
reproducibility because the competition of the codeine and codeine-
d6 for the metal surface used for SERS 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Representative PLS based predictions of concentration versus known concentrations of (a) codeine and (c) mixtures of codeine + codeine-d6 
spiked in plasma. Note that the concentration of codeine-d6 remained constant. The corresponding PLS loading plots are from (b) codeine alone, and (d) 
after employing the isotopic labelling with codeine-d6. 
 
 
 
 
 
Table 1 Comparison of PLSR models showing their reproducibility and 
accuracy of predicting codeine concentrations spiked to water and plasma 
 
 
 Water   Plasma  
       
  Codeine +   Codeine + 
Metric Codeine codeine-d6 Codeine codeine-d6 
Factors 9 9  9 9 
R2 0.9993 0.9993  0.9993 0.9994 
Q2 0.7418 0.7898  0.8895 0.9389 
RMSEP 11.4107 7.7543  18.7416 12.7135 
RMSECV 11.4655 8.6613  11.3560 8.4436 
 
Factors specify the number of latent variables used in PLSR; RMSEP, root-
mean-squared error of prediction (from the test set); RMSECV root mean 
squared error of cross validation (from the training set); R2 and Q2 show 
linearity for the training and test sets predictions respectively. 
 
 
is equal and this will compensate for any diﬀ erence in the number of 
nanoparticles under analysis or any fluctuations in laser fluence 
which are known to aﬀ ect quantification. The main bands aﬀ ected 
by the presence of the heavy isotope were found to be at 2953, 3028 
and 3059 cm−1 corresponding to the symmetric C–H stretching of 
N–CH3, symmetric C–H stretching of O–CH3, and asymmetric C–H 
stretching of O–CH3, respect-ively. These were shifted to 2075, 
2128 and 2275 cm−1 assigned to N–CD3, O–CD3 and O–CD3 in the 
codeine-d6 isotopolog. DFT 
 
calculations were employed in order to support the vibrational 
assignments of codeine and codeine-d6 and these were in agree-ment 
with our experimental findings. The LOD of codeine in both water 
and plasma were 0.7 µM (209.55 ng mL−1) and 1.39 µM (416.12 ng 
mL−1), respectively. Future work is required to improve the LOD of 
the codeine SERS signal to reach the detection level that is expected 
for clinical samples (9.7 to 210 ng mL−1),45 where we could use 
superhydrophobic wires with hydrophilic tips which would allow us 
to improve the LOD of codeine46 or concentrate the sample prior to 
analyses by evaporation. Despite the fact that the detection limit is 
not yet clinically useful these findings clearly demonstrate the 
potential application of SERS when combined with internal isotope 
stan-dards as a portable technique that could be readily and remo-
tely deployed for on-site testing in clinical settings. 
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